The Protein Fractionation Technology Working Party published a report advising that, in order to reduce the need for purchasing overseas blood products, BPL needed to produce 450,000 litres of plasma annually. Read more about The Protein Fractionation Technology Working Party published a report advising that, in order to reduce the need for purchasing overseas blood products, BPL needed to produce 450,000 litres of plasma annually.
Dr Lane wrote a letter to Dr Jones concerning the difference in pool sizes between commercial and non-commercial concentrate products. Read more about Dr Lane wrote a letter to Dr Jones concerning the difference in pool sizes between commercial and non-commercial concentrate products.
A report to the Advisory Sub-committee on Blood Products and Blood Group Reference Laboratories of the Central Committee of the National Blood Transfusion Service was published. Read more about A report to the Advisory Sub-committee on Blood Products and Blood Group Reference Laboratories of the Central Committee of the National Blood Transfusion Service was published.
Dr Lane wrote a letter to Professor Mollison enclosing the paper submitted to DHSS on "Stop Gap Provision for Plasma Fractionation at BPL". The paper outlined the problems of containing hepatitis in the preparation of concentrates and the programme to provide radioimmunoassay service to contain Hepatitis B. Read more about Dr Lane wrote a letter to Professor Mollison enclosing the paper submitted to DHSS on "Stop Gap Provision for Plasma Fractionation at BPL". The paper outlined the problems of containing hepatitis in the preparation of concentrates and the programme to provide radioimmunoassay service to contain Hepatitis B.
A note of a discussion held at the DHSS (in January 1978) regarding RIA testing to contain hepatitis at BPL recorded agreement that Dr Lane would revise his paper to include information about the additional staff, accommodation and costs necessary to introduce RIA at BPL, and that this would be shown to the Medicines Division. Read more about A note of a discussion held at the DHSS (in January 1978) regarding RIA testing to contain hepatitis at BPL recorded agreement that Dr Lane would revise his paper to include information about the additional staff, accommodation and costs necessary to introduce RIA at BPL, and that this would be shown to the Medicines Division.
Dr Lane wrote to Thomas Dutton, of the DHSS, enclosing a paper on the requirement for hepatitis testing at BPL, in relation to the stop-gap provisions for plasma fractionation at BPL. He said the paper was to enable Mr Dutton to see what he thought about this matter prior to planned discussions with Dr Waiter and Dr Maycock at DHSS. Read more about Dr Lane wrote to Thomas Dutton, of the DHSS, enclosing a paper on the requirement for hepatitis testing at BPL, in relation to the stop-gap provisions for plasma fractionation at BPL. He said the paper was to enable Mr Dutton to see what he thought about this matter prior to planned discussions with Dr Waiter and Dr Maycock at DHSS.
The product labels for BPL Factor 8 concentrate in March 1976 noted: "less than 1500 plasma donations used in the preparation of this batch". Read more about The product labels for BPL Factor 8 concentrate in March 1976 noted: "less than 1500 plasma donations used in the preparation of this batch".
In June 1985, a document about the BPL (specifically background and current information) about the facility was produced for members of the CBLA. It detailed its product list, manufacturing targets, revenue and its position on self-sufficiency and meeting the demand for plasma, amongst other topics. Read more about In June 1985, a document about the BPL (specifically background and current information) about the facility was produced for members of the CBLA. It detailed its product list, manufacturing targets, revenue and its position on self-sufficiency and meeting the demand for plasma, amongst other topics.
Dried Factor 8 Fraction heat-treated from BPL noted on its label that: "this product prepared from human venous plasma, is heat-treated in its final container to reduce the risk of viral infections (including HIV and hepatitis) but freedom from this risk cannot be assumed." Read more about Dried Factor 8 Fraction heat-treated from BPL noted on its label that: "this product prepared from human venous plasma, is heat-treated in its final container to reduce the risk of viral infections (including HIV and hepatitis) but freedom from this risk cannot be assumed."
Dried Factor 8 Fraction from BPL (Batch 8Y 3607) was approved for clinical use. The product label noted that: "the preparation is of human origin. It has been heat treated, in the vial, to reduce the risk of infection by viral agents (including hepatitis and AIDS viruses) but it cannot be assumed to be free from the risk of transmission of viral infections." Read more about Dried Factor 8 Fraction from BPL (Batch 8Y 3607) was approved for clinical use. The product label noted that: "the preparation is of human origin. It has been heat treated, in the vial, to reduce the risk of infection by viral agents (including hepatitis and AIDS viruses) but it cannot be assumed to be free from the risk of transmission of viral infections."